Principal Financial Group Inc. Buys 43,589 Shares of Privia Health Group, Inc. $PRVA

Principal Financial Group Inc. increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 1.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,787,802 shares of the company’s stock after purchasing an additional 43,589 shares during the quarter. Principal Financial Group Inc.’s holdings in Privia Health Group were worth $66,099,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PRVA. Canada Pension Plan Investment Board increased its stake in shares of Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after acquiring an additional 1,200 shares in the last quarter. GAMMA Investing LLC increased its stake in Privia Health Group by 198.5% during the 4th quarter. GAMMA Investing LLC now owns 4,314 shares of the company’s stock valued at $102,000 after purchasing an additional 2,869 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Privia Health Group during the 2nd quarter valued at $113,000. Covestor Ltd increased its stake in Privia Health Group by 39.8% during the 3rd quarter. Covestor Ltd now owns 5,824 shares of the company’s stock valued at $145,000 after purchasing an additional 1,657 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Privia Health Group during the 1st quarter valued at $154,000. Institutional investors own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays boosted their price target on shares of Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 25th. Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a report on Friday, January 9th. They set an “outperform” rating and a $31.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $36.00 price target on shares of Privia Health Group in a report on Thursday, February 26th. Citigroup lowered their price target on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Finally, Truist Financial increased their price target on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.31.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CEO Parth Mehrotra sold 41,999 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $22.86, for a total transaction of $960,097.14. Following the transaction, the chief executive officer directly owned 343,795 shares in the company, valued at $7,859,153.70. This trade represents a 10.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Matthew Shawn Morris sold 17,096 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04. Following the transaction, the director owned 68,188 shares in the company, valued at $1,704,018.12. The trade was a 20.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 274,255 shares of company stock worth $6,299,092 over the last ninety days. Insiders own 5.70% of the company’s stock.

Privia Health Group Stock Performance

PRVA stock opened at $23.99 on Friday. The company’s 50 day moving average is $22.73 and its 200 day moving average is $23.34. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 141.12, a price-to-earnings-growth ratio of 1.50 and a beta of 0.96. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.11. The company had revenue of $603.85 million for the quarter, compared to analysts’ expectations of $560.99 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. Privia Health Group’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.22 earnings per share. As a group, sell-side analysts forecast that Privia Health Group, Inc. will post 0.37 EPS for the current fiscal year.

More Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Reported Q1 results showed material revenue outperformance (company: $603.9M vs. street ~$561M) and management reiterated FY‑2026 revenue guidance (~$2.4B–$2.5B), supporting growth expectations. Privia Health Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Some previews and follow‑ups highlight key metrics investors will parse (patient volumes, margin trends, and guidance drivers) rather than create a clear directional read until the conference call details are digestible. What to expect from Privia Health’s (PRVA) Q1 earnings
• Neutral Sentiment: Coverage is mixed on the underlying EPS figure (some outlets cite a beat while others report a miss), creating short‑term noise as investors reconcile the company release, third‑party estimates and timing/adjustments. Privia Health (PRVA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• Negative Sentiment: Insider selling from senior executives (CFO sales under a 10b5‑1 plan) has been disclosed recently; while pre‑arranged plans lessen governance concerns, the transactions can pressure near‑term sentiment. Privia Health (PRVA) Insider Selling
• Negative Sentiment: Director share sales (also under 10b5‑1 plans) add to the near‑term supply narrative and may offset some of the positive reaction to top‑line strength. Director Matthew Shawn Morris Sells Shares

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.